Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Teniposide

FDA-approved product (injectable, injection), marketed as Vumon.

Registered studies
30
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Teniposide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Podophyllotoxin derivatives
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA48.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli41.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae28.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis38.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

30registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Teniposide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Teniposide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL

    NCT07185373 · start 2025-10-01

    Registered record
    Registry ID
    NCT07185373
    Conditions
    Primary Central Nervous System Lymphoma
    Interventions
    Teniposide; Orelabrutinib; MTX; Rituximab (R); Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Recruiting
    Start
    2025-10-01
    Completion
    2029-07-30
    Enrolment
    215

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Central Nervous System Lymphoma
    InterventionTeniposide; Orelabrutinib; MTX; Rituximab (R) +1 more
    PhasePhase 2 / Phase 3
    Registry statusRecruiting

  • Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer

    NCT06758700 · start 2025-02-07

    Registered record
    Registry ID
    NCT06758700
    Conditions
    Extensive-stage Small Cell Lung Cancer (ES-SCLC); Thoracic Neoplasms; Lung Neoplasms; Lung Diseases
    Interventions
    Teniposide administration
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-02-07
    Completion
    2026-12-31
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionExtensive-stage Small Cell Lung Cancer (ES-SCLC); Thoracic Neoplasms; Lung Neoplasms; Lung Diseases
    InterventionTeniposide administration
    PhasePhase 2
    Registry statusRecruiting

  • Combination Regimen of Teniposide, PD-1 Monoclonal Antibody and Selinixor for Patients With Relapsed or Refractory PCNSL

    NCT07074470 · start 2025-01-02

    Registered record
    Registry ID
    NCT07074470
    Conditions
    Primary Central Nervous System Lymphoma (PCNSL)
    Interventions
    Induction therapy-2 cycles of VPX (Teniposide, PD-1 monoclonal antibody plus Selinixor); Consolidation therapy with ASCT after TB (Thiotepa plus Busulfan) preconditioning; Consolidation therapy-4 cycles of VPX (Teniposide, PD-1 monoclonal antibody plus Selinixor); Consolidation therapy-whole brain radiation therapy; Maintenance treatment-PD-1 monoclonal antibody
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2025-01-02
    Completion
    2032-01-02
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Central Nervous System Lymphoma (PCNSL)
    InterventionInduction therapy-2 cycles of VPX (Teniposide, PD-1 monoclonal antibody plus Selinixor); Consolidation therapy with ASCT after TB (Thiotepa plus Busulfan) preconditioning; Consolidation therapy-4 cycles of VPX (Teniposide, PD-1 monoclonal antibody plus Selinixor); Consolidation therapy-whole brain radiation therapy +1 more
    PhaseNot applicable
    Registry statusRecruiting

  • Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS

    NCT06692491 · start 2025-01-01

    Registered record
    Registry ID
    NCT06692491
    Conditions
    Rare Tumour
    Interventions
    Albumin-Bound Paclitaxel; Epirubicin; Gemcitabine; Vinorelbine; Cisplatin; Irinotecan; Fluorouracil; Nivolumab; Pembrolizumab; Durvalumab; Atezolizumab; Sintilimab; Tislelizumab; Camrelizumab; Toripalimab; Serplulimab; Adebrelimab; Envafolimab; Osimertinib; Alectinib; Vemurafenib; Pamiparib; Pyrotinib; Imatinib; Palbociclib; Savolitinib; Entrectinib; Other
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2025-01-01
    Completion
    2029-12-31
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRare Tumour
    InterventionAlbumin-Bound Paclitaxel; Epirubicin; Gemcitabine; Vinorelbine +24 more
    PhasePhase 2
    Registry statusNot yet recruiting

  • Treatment of Newly Diagnosed Central Malignant Germ Cell Tumor People With Teniposide Injection Combined With Cisplatin.

    NCT07188441 · start 2024-08-13

    Registered record
    Registry ID
    NCT07188441
    Conditions
    GCT; Germ Cell Tumor; Central Malignant Germ Cell Tumor
    Interventions
    Teniposide Injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-08-13
    Completion
    2026-12
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGCT; Germ Cell Tumor; Central Malignant Germ Cell Tumor
    InterventionTeniposide Injection
    PhasePhase 2
    Registry statusRecruiting

  • Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study

    NCT07583511 · start 2024-02-01

    Registered record
    Registry ID
    NCT07583511
    Conditions
    Small-cell Lung Cancer
    Interventions
    Teniposide; Etoposide; serplulimab; cisplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-02-01
    Completion
    2027-12-01
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSmall-cell Lung Cancer
    InterventionTeniposide; Etoposide; serplulimab; cisplatin
    PhasePhase 2
    Registry statusRecruiting

  • Teniposide Incorporating Bu/Cy Conditioning Regimen for HLH With Central Nervous System Involvemen

    NCT06048107 · start 2023-10-22

    Registered record
    Registry ID
    NCT06048107
    Conditions
    HLH
    Interventions
    Teniposide
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2023-10-22
    Completion
    2025-09-30
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHLH
    InterventionTeniposide
    PhaseNot applicable
    Registry statusUnknown

  • GTP Regimen in the Treatment of Refractory/Recurrent HLH

    NCT06038422 · start 2023-09-15

    Registered record
    Registry ID
    NCT06038422
    Conditions
    Refractory; Recurrence; Hemophagocytic Lymphohistiocytosis
    Interventions
    GTP regimen
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2023-09-15
    Completion
    2025-09-15
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRefractory; Recurrence; Hemophagocytic Lymphohistiocytosis
    InterventionGTP regimen
    PhasePhase 3
    Registry statusUnknown

  • Online Group Therapy for Breast Cancer

    NCT05259267 · start 2022-01-15

    Registered record
    Registry ID
    NCT05259267
    Conditions
    Breast Cancer
    Interventions
    Online Group Therapy for PTG; Online Support Group
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2022-01-15
    Completion
    2022-10
    Enrolment
    51

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionOnline Group Therapy for PTG; Online Support Group
    PhaseNot applicable
    Registry statusUnknown

  • Influence of the Operative Day on the Average Duration of Stay in Primary Hip and Knee Replacements

    NCT03132831 · start 2018-09-01

    Registered record
    Registry ID
    NCT03132831
    Conditions
    Length of Stay; Arthroplasty
    Interventions
    Determine the DMS of the Total Hip Prosthesis of the University Hospital of Amiens (PTH) and the Total Knee Prosthesis (PTG)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-09-01
    Completion
    2018-12-01
    Enrolment
    1,663

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLength of Stay; Arthroplasty
    InterventionDetermine the DMS of the Total Hip Prosthesis of the University Hospital of Amiens (PTH) and the Total Knee Prosthesis (PTG)
    PhaseNot recorded
    Registry statusCompleted

  • Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma

    NCT02788201 · start 2017-03-27

    Registered record
    Registry ID
    NCT02788201
    Conditions
    Urothelial Carcinoma; Bladder Cancer; Urinary Bladder Neoplasms
    Interventions
    75 approved agents; COXEN
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-03-27
    Completion
    2019-10-23
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrothelial Carcinoma; Bladder Cancer; Urinary Bladder Neoplasms
    Intervention75 approved agents; COXEN
    PhasePhase 2
    Registry statusCompleted

  • ATG Could Improve the Outcome Of Hematopoietic Stem Cell Transplant in Patients With Highly Aggressive T Cell Tumors

    NCT02290132 · start 2013-08

    Registered record
    Registry ID
    NCT02290132
    Conditions
    Acute Lymphoblastic Leukemia; Lymphoblastic Lymphoma
    Interventions
    Rabbit Anti-human Thymocyte Globulin (ATG)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2013-08
    Completion
    2017-07
    Enrolment
    63

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Lymphoblastic Leukemia; Lymphoblastic Lymphoma
    InterventionRabbit Anti-human Thymocyte Globulin (ATG)
    PhaseNot recorded
    Registry statusUnknown

  • Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma

    NCT01700946 · start 2013-04-15

    Registered record
    Registry ID
    NCT01700946
    Conditions
    Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood B-Lymphoblastic Lymphoma
    Interventions
    dexamethasone; vincristine sulfate; rituximab; clofarabine; cyclophosphamide; etoposide; aldesleukin; pegaspargase; methotrexate; mercaptopurine; cytarabine; mitoxantrone; teniposide; vinblastine; natural killer cell infusion; laboratory biomarker analysis; therapeutic hydrocortisone; allogeneic hematopoietic stem cell transplantation; CliniMACS
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-04-15
    Completion
    2021-07-24
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent B-Cell Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood B-Lymphoblastic Lymphoma
    Interventiondexamethasone; vincristine sulfate; rituximab; clofarabine +15 more
    PhasePhase 2
    Registry statusCompleted

  • Treatment of Primary CNS Lymphoma

    NCT01960192 · start 2012-06

    Registered record
    Registry ID
    NCT01960192
    Conditions
    Primary CNS Lymphoma (PCNSL)
    Interventions
    HD-MTX-Ara-C regimen; FVD regimen
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2012-06
    Completion
    2020-06
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary CNS Lymphoma (PCNSL)
    InterventionHD-MTX-Ara-C regimen; FVD regimen
    PhasePhase 4
    Registry statusUnknown

  • Trial of Endostar Combined With CHOPT for T Cell Lymphoma

    NCT01430013 · start 2011-06

    Registered record
    Registry ID
    NCT01430013
    Conditions
    T Cell Lymphoma
    Interventions
    Endostar and CHOPT
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2011-06
    Completion
    2015-12
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionT Cell Lymphoma
    InterventionEndostar and CHOPT
    PhasePhase 2
    Registry statusUnknown